AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00479934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: 6 month treatment with 400mg/day (per os)
Study NCT00479934 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: imatinib mesylate
Description: 6 month treatment with 400mg/day (per os)
Study NCT03147573 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 1-hour blood pressure monitoring (1BPM)
Description: This method consists of performing blood pressure measurements programmed at 5-min intervals over 1 hour. Two extra recordings taken at the start and end of this period are discarded. Blood pressure is measured in a quiet room at the same health centre.
Study NCT03147573 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 24-hour ambulatory blood pressure monitoring (ABPM)
Description: The device is programmed to record the participant's BP every 20 min and 30 min during the day and night, respectively. Participants are advised to carry on with their normal daily activities, avoiding any intense physical exertion, and to remain at rest when their BP is being measured.
Study NCT03147573 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Office blood pressure measurement (OBPM)
Description: Two readings were made one minute apart with a validated automatic sphygmomanometer in a sitting position after five minutes of rest. The average of two readings is calculated. The procedure is repeated during 3 office visits at least a week apart.
Study NCT03147573 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring (HBPM)
Description: For each blood pressure recording, at least two consecutive measurements should be taken, at least one minute apart. Blood pressure should be recorded twice daily, ideally in the morning and evening. Blood pressure recording should continue for at least four consecutive days, ideally seven. The average of the above readings should be calculated, ignoring the first day.
Study NCT02373306 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sustained or hemodynamically unstable arrhythmia induction during non-invasive programmed stimulation
Study NCT00287846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Study NCT02619006 — intervention group
Intervention type: OTHER
Intervention: Delayed Cord Clamping or Cord Milking
Description: Healthy term infants who were previously randomized or assigned at birth to the intervention group known as delayed cord clamping. The cord was clamped and cut at or beyond 300 seconds (5 mins). Cord milking (cord milked x 5) was used as a proxy for delayed cord clamping when there was a clinical situation of concern.
Study NCT00864344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline HCl 100 mg tablets, single dose
Description: A: Experimental SSubjects received Purepac formulated products under fasting conditions
Study NCT00864344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoloft® 100 mg tablets, single dose
Description: B: Active comparator Subjects received Pfizer formulated products under fasting conditions
Study NCT01517828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sedation by ketamine
Description: Kétamine (50mg/5ml, Panpharma): for a posology of 2 mg/kg: dose of 0.2 ml/kg Intranasal administration with a 1 ml syringe. Kétamine is a derivated of phencyclidine with a sedative, anesthesic, analgesic and amnesiant activity. Ketamine keeps also a protective reflex of upper respiratory tracts.~One injection will be done and if after 7 minutes, newborn is not correctly sedated another dose of same product will be done.
Study NCT01517828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sedation with Midazolam
Description: Midazolam (phyal of 5mg/5ml, Mylan S.A.S.) for a posology of 0.2 mg/kg: dose of 0.2 ml/kg Instillation in intranasal with a syringe of 1 ml. Midazolam is an imidazobenzodiazépine, witj a sedative and hypnotic activity,anxiolytic, anti convulsive and muscle relaxant proprieties.~One injection will be done and if after 7 minutes, newborn is not correctly sedated another dose of same product will be done.
Study NCT02949713 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messaging-motivational interviewing
Description: Interactive weekly mobile phone text messaging plus prospective motivational interviews
Study NCT00977587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saccharomyces Cerevisiae CNCM I-3856
Description: Saccharomyces cerevisiae CNCM I-3856, 500 mg per capsule (5 X109 living cells). Living cells are estimated by the method of colony forming units (cfu).subjects will take 1 capsule twice a day
Study NCT00977587 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo: Capsules will contain 500 mg of the following formulation and will not contain Saccharomyces cerevisiae CNCM I-3856:~* Calcium phosphate, Dibasic 472.0 mg~* Maltodextrin DE14 112.1 mg~* Vegetal magnesium stearate 5.9 mg subjects will take one capsule twice a day
Study NCT02408926 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix
Description: Pregnant women will be vaccinated with an acellular pertussis containing vaccine between 27 and 36 weeks of gestation.
Study NCT02408926 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Boostrix
Description: Pregnant women will be vaccinated with an acellular pertussis containing vaccine between 27 and 36 weeks of gestation.
Study NCT02408926 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa
Description: Children from group A will be vaccinated with an acellular pertussis containing vaccine according to the official recommendations in Thailand at 2, 4, 6 and 18 months.
Study NCT02408926 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quinvaxem
Description: Children from group B will be vaccinated with a whole cell pertussis containing vaccine according to the official recommendations in Thailand at 2, 4, 6 and 18 months.
Study NCT02408926 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: OPV
Description: Children from group B will be vaccinated with OPV vaccine according to the official recommendations in Thailand at 2, 4, 6 and 18 months.
Study NCT03423563 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexible fiberoptic bronchoscopy
Description: Flexible fiberoptic bronchoscopy versus flexible intubation video endoscope regarding intubation time in obese patients
Study NCT03423563 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fexible intubation video endoscopy
Description: Fexible intubation video endoscopy
Study NCT04628598 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Antenatal care and prenatal education with a home visit
Description: Providing prenatal education and care by home visits to pregnant women
Study NCT01927068 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stellarex 0.035 Over-the-Wire (OTW) drug-coated angioplasty balloon (Stellarex DCB)
Description: Percutaneous Transluminal Angioplasty will be completed using a 2.0 micrograms per square millimeter. Paclitaxel-Coated Balloon. Balloon will be inflated to a size appropriate for the target vessel, as determined by the physician. Total balloon inflation time is determined by the physician, but no less than one minute.
Study NCT00044213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EDTA
Description: Participants will receive 40 infusions of standard chelation solution.
Study NCT00044213 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: EDTA
Description: Participants will receive 40 infusions of standard chelation solution.
Study NCT00044213 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: EDTA Placebo
Description: Participants will receive 40 infusions of EDTA placebo.
Study NCT00044213 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High Dose Vitamin
Study NCT00044213 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: High Dose Vitamin
Study NCT00044213 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: High Dose Vitamin Placebo
Study NCT04555408 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: blue light
Description: Patients receive exposure to 100lux blue light, which dominant wave-length is 468nm for 30 minutes in the morning.
Study NCT04555408 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bright light
Description: Patients receive exposure to 1000lux bright light, which dominant wave-length is 490nm for 30 minutes in the morning.
Study NCT04555408 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: dim light
Description: Patients receive exposure to 100lux dim light, which dominant wave-length is 490nm for 30 minutes in the morning.
Study NCT03895918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Activity
Description: Undergo parenting skills intervention
Study NCT03895918 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient Monitoring
Description: Undergo medication adherence monitoring
Study NCT03895918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01762527 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adaptive Radiotherapy
Description: CTCAE scoring baseline, every 2'nd week during RT, 2 weeks, 3, 12 and 24 month after RT cineMR (time resolved MR) baseline and weekly during RT for intra fractional motion
Study NCT03299452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non Chemotherapy
Description: Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines.
Study NCT03299452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy and target therapy
Description: Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines.
Study NCT03299452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese herb medicine
Description: Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines.
Study NCT02527564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Study NCT02527564 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00493441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVN944
Description: 150, 200, 250, 300, or 400 mg q12h
Study NCT01952093 — intervention group
Intervention type: BEHAVIORAL
Intervention: Home-based intervention program
Description: The intervention had been done in the previous intervention study. The intervention included in-hospital and after-discharge service. After-discharge intervention performed at 0, 1, 2, 4, 6, 9, 12 months of age at the home.
Study NCT01952093 — intervention group
Intervention type: BEHAVIORAL
Intervention: Clinic-based intervention program
Description: The intervention had been done in the previous intervention study. The intervention included in-hospital and after-discharge service. After-discharge intervention performed at 0, 1, 2, 4, 6, 9, 12 months of age at the clinic.
Study NCT02060968 — intervention group
Intervention type: DEVICE
Intervention: Promus PREMIER
Study NCT01505660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care management
Description: The intervention will include healthcare delivery team notification of patient reported outcomes (PROs) including medication adherence and adherence barriers such as depression symptoms along with intervention recommendations and targeted care management using a stepped care approach. Patients will receive structured calls from their care manager 2 and 6 weeks after enrollment. An assessment including depression, adherence, and substance use will be completed at the beginning of each call. After the 2nd call, a stepped care approach will be used where patients with a greater need based on adherence and depression will receive more intensive interventions based on the PEARL intervention. The components include: a) problem solving treatment, b) social and physical activation, c) pleasant events scheduling, d) patient support and education regarding medication use, and e) medical and psychiatric consultation. Patients will also receive follow-up calls at \~9 and 12 months after enrollment.
Study NCT02198560 — intervention group
Intervention type: DEVICE
Intervention: RS-3000 Lite
Study NCT04633031 — intervention group
Intervention type: DEVICE
Intervention: Boston
Study NCT04633031 — intervention group
Intervention type: DEVICE
Intervention: Cheneau
Study NCT03683043 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Long GnRH agonist protocol
Description: 8. The patients follow long protocol, which includes down regulation starting on day 21 of the previous cycle. The patient is seen after 14 days to confirm down regulation. Serum E2 ≤ 50 pg/ mL and no ovarian cysts observed in transvaginal US.~9. Induction is started on day 3 of the current cycle by gonadotrophins (FSH and LH) daily IM or SC injections provided that the different preparations at the market can be used.
Study NCT03683043 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Embryo transfer
Description: Cusco speculum was used to allow access to the cervix. The vagina was flushed by saline, and the cervical mucus is removed by Q-tips and/ or suction tubes. In few cases, where patients had long vaginae; two Sims' speculums were used to spread the vaginal anterior and posterior vaginal walls apart. In these cases, the attending nurse assisted the gynecologists during transfer The gynecologist asks the embryologist to load the embryos in the transfer catheter, and the gynecologist receives the loaded catheter from a window connecting the lab and operating room. In cases of trans-vaginal ultrasound guided embryo transfer the embryologist hands in the catheter to the gynecologists in the outer sheath and the gynecologist injects slowly the fluid containing the embryo/s. All patients are asked to rest for 30 minutes after the transfer
Study NCT02837809 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low dose CT
Description: annual CT vs biennial CT
Study NCT02699671 — intervention group
Intervention type: DEVICE
Intervention: Bioresorbable Vascular Scaffold
Study NCT00995267 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: parent-child interaction/activities based on Adler's methods
Description: Description of the Intervention:~5 joint classroom activities (parents and children together, involving children in food choices/food preparation-sense of belonging/decision making): 1. Healthy breakfasts and 10 o'clock snacks 2. Fats and oils in the diet, cooking methods, setting limits to oily food intake. 3. Fruit and vegetables in the daily diet, adults as role models. 4. Learning about food categories \& pyramid, healthy eating and growth. 5. Limiting consumption of sweets and snacks.~Workshop for Parents: Explaining nutritional needs of children; how to encourage good eating habits, how to deal with children's manipulations, providing tools to elicit change; use of food to attract parental attention; practical tools to deal with their children's eating habits/obesity/refusal to eat/chronic health problems/failure to grow; ways to prevent use of food as an answer to childhood frustrations.
Study NCT03199144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: 3 cycles of Gemzar-Abraxane
Study NCT03199144 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy
Description: Stereotactic radiation treatment delivering 30 Gy in 5 fractions over 9 days
Study NCT03199144 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Whipple procedure will be the recommended procedure but will be modified according to the initial tumor location
Study NCT01922739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone ER
Description: Participants were instructed to take hydrocodone ER tablets orally with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating.
Study NCT01922739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: During the double-blind titration period used in the original protocol, placebo tablets matching each dose of hydrocodone bitartrate ER tablets (active drug) were used to maintain the blind but not for purposes of comparison.
Study NCT00107172 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Study NCT00107172 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Study NCT00107172 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Study NCT01038089 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: Resveratrol
Study NCT03389269 — intervention group
Intervention type: OTHER
Intervention: Meal test
Description: 240 min mixed meal test with aspiration using AspireAssist.
Study NCT03529851 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weekly questionnaires
Description: In case of alarming symptoms reported in the questionnaire, an alert is automatically sent to the hospital. The clinicians will contact the patient, confirm the symptoms and intervene according to standard practice.
Study NCT03949361 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Indirect calorimetry
Description: Resting energy expenditure
Study NCT03736551 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5:2 diet
Description: very low energy diet (600 kcal/day) on 2 consecutive days of the week, and 5 days each week on an energy restricted diet to maintain a similar overall energy deficit of 600 kcal/day across the week (5:2 diet)
Study NCT03736551 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Renal Weight Management Programme
Description: Dietary intervention includes a standard continuous energy restricted diet aimed at reducing daily energy intake by 600 kcal/day relative to their estimated total energy expenditure. In addition to the dietary intervention, the programme also includes personal exercise plans, optional pharmacotherapy (orlistat at standard dose), and development of personalised dietary and exercise goals using behavioural therapy techniques and motivational interviewing.
Study NCT03736551 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Renal Weight Management Programme
Description: Dietary intervention includes a standard continuous energy restricted diet aimed at reducing daily energy intake by 600 kcal/day relative to their estimated total energy expenditure. In addition to the dietary intervention, the programme also includes personal exercise plans, optional pharmacotherapy (orlistat at standard dose), and development of personalised dietary and exercise goals using behavioural therapy techniques and motivational interviewing.
Study NCT01519349 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV1.CMV.huFollistatin344
Description: * First cohort - Low Dose: 2E11 vg/kg with single leg injection (n=3 sIBM)~* Second cohort: 3E11 vg/kg per quad (n=3 sIBM; 3 BMD)~* Third cohort: 6E11 vg/kg per quad (n=3 sIBM; 3 BMD)
Study NCT05270083 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: NeuraCeq PET imaging with intravenous (IV) dose of 300MBq of Neuraceq™ ([F-18]Florbetaben)
Description: Participants will receive an intravenous (IV) dose of 300 MBq of Neuraceq™ in a volume of 10 mL or less. A 30 minute duration PET image will be acquired starting immediately after Neuraceq™ injection. A second 20-minute duration PET image will be acquired starting 90 minutes after Neuraceq™ injection.
Study NCT03051269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium chloride
Description: Tumour site is injected with a solution of 9 mg/ml calcium chloride and afterwards the tumour site is given electroporation to facilitate calcium to enter the cell cytosol.
Study NCT03051269 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroporation
Description: Performed by single use electrodes attaches to a device called Cliniporator provided from IGEA, ITALY.
Study NCT00187044 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PolyEnv1 vaccine
Description: administered subcutaneously as 10\*7 pfu in 0.8 mL
Study NCT03949361 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Skin Temperature
Description: Temperature: supraclavicular, infraclavicular, abdominal, mid-thigh, non-dominant lower arm, middle finger tip, left lower leg, left dorsal foot, ear thermometer
Study NCT03949361 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dual energy X-ray Absorptiometry (DXA)
Description: Body composition
Study NCT03949361 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Sampling
Description: thyroid-stimulating hormone (TSH), free triiodothyronine (fT3), free thyroxine (fT4), HbA1c, Fibroblast growth factor 21 (FGF21)
Study NCT03949361 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: FDG-PET
Description: Dynamic PET scanning of the neck-region
Study NCT03419507 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal tube introducer
Description: The doctors that drawed envelop number 2 will be asked to intubate with laryngoscope by the adult size, endotracheal tube introducer with using No. 3 Macintosh blade
Study NCT03419507 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh laryngoscopy
Description: The doctors who drawed envelope number 1 will asked to intubate with using No. 3 Macintosh blade
Study NCT01341782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paricalcitol
Study NCT01341782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: maxacalcitol